Skinvisible Inc. Expands Product Line, Launches Skinvisible(TM) "Personal" Formulation

LAS VEGAS, April 13 /PRNewswire/ -- Skinvisible Inc. (OTC Bulletin Board: SKVI) announced today that it has launched Skinvisible(TM)"Personal" formulation, the fifth lotion in its novel and proprietary protect-the-skin family of products. Data from independent studies involving human subje...

Full description

Saved in:
Bibliographic Details
Published inPR Newswire p. 1
Format Newsletter
LanguageEnglish
Published New York PR Newswire Association LLC 13.04.1999
Subjects
Online AccessGet full text

Cover

More Information
Summary:LAS VEGAS, April 13 /PRNewswire/ -- Skinvisible Inc. (OTC Bulletin Board: SKVI) announced today that it has launched Skinvisible(TM)"Personal" formulation, the fifth lotion in its novel and proprietary protect-the-skin family of products. Data from independent studies involving human subjects suggest the patent- pending Skinvisible(TM) protective lotion may dramatically reduce the extensive and escalating incidence of common hand dermatitis caused by noxious chemicals and/or repeated contact with soap and water, both at home and at work. Additionally, findings of independent in vivo and in vitro studies conclude Skinvisible(TM) demonstrates superior bacteriostatic and/or bacteriocidal effects against a broad spectrum of test pathogens within one (1) minute of contact -- including organisms demonstrating marked antimicrobial resistance to antibiotics. Full text of these studies are available at www.skinvisible.com. "We believe that use of Skinvisible at recommended intervals could significantly reduce the incidence of hand dermatitis in the home, industrial settings, healthcare facilities, food-handling services and salon environments, wherever repetitive contact with water and detergents are the primary cause of the disease," said Terry Howlett, President and Chief Executive Officer of Skinvisible Inc. "Equally important, Skinvisible lotion is very effective at killing pathogens, particularly the two significant pathogens recognized by the healthcare industry as the superbugs: methicillin- resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus faecalis (VRE)."